AGILITY INNOVATION EXECUTION AND EXPANSION - Talented, experienced management team driving the sector's fastest growth in customers, revenues and ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
AGILITY INNOVATION EXECUTION AND EXPANSION Talented, experienced management team driving the sector's fastest growth in customers, revenues and shareholder value APRIL 2018
Forward Looking Statements This Presentation (the “Document”) by Aurora Cannabis Inc. (“Aurora” or the “Company”) has been compiled by management of the Company solely for information purposes. The Document has been prepared and dated as of March 31, 2017, and the information contained herein is current as of such date only. The Document under no circumstances is to be construed to be an offering of securities. Neither this Document, nor its delivery to the recipient shall constitute an offer to sell, or the solicitation of an offer to buy the assets described herein. It is provided solely for use by prospective investors in considering their interest. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its business and does not purport to contain all the information that prospective investors may require. Prospective investors should conduct their own investigation and analysis of the Company and its business and the information contained in this Document as well as any additional information provided by the Company. This Document includes forward-looking statements within the meaning of certain securities laws, including the “safe harbour” provisions of the Securities Act (Ontario, Alberta and British Colombia) and other provincial securities law in Canada. These forward- looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words “may”, “will”, “could”, “should”, “would”, “suspect”, “outlook”, “believe”, “plan”, “anticipate”, “estimate”, “expect”, “intend”, “forecast”, “objective” and “continue” (or the negative thereof), and words and expressions of similar import, are intended to identify forward- looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. The Company strongly cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond our control, could cause the Company’s actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to: general economic conditions; pending and proposed legislative or regulatory developments in Canada including the impact of changes in laws, regulations and the enforcement thereof; reliance on funding models in Canada; operational and infrastructure risks including possible equipment failure and performance of information technology systems; intensifying competition resulting from established competitors and new entrants in the businesses in which the Company operates; insurance coverage of sufficient scope to satisfy any liability claims; fluctuations in total patients and customers; technological change and obsolescence; loss of services of key senior management personnel; privacy laws; structural subordination of common shares; leverage and restrictive covenants; fluctuations in cash timing and amount of capital expenditures; tax-related risks; unpredictability and volatility of the price of the Company’s securities; dilution; and future sales of the Company’s securities. The foregoing list of important factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Except as required by Canadian securities law, the Company does not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by the Company or on the Company’s behalf. Such statements speak only as of the date made. The forward-looking statements contained in this Document should not be relied upon as representing the view of the Company or its management as of any date subsequent to the date of this Document. Neither the Company nor its management is under any obligation, and neither undertakes, to update any of this information at any particular time. Neither the Company nor its management assumes any obligation to update or revise forward-looking statements should circumstances or estimates or opinions changes. None of the Company or its affiliated or related partnerships and corporations or their respective directors, officers, partners, employees, agents or representatives makes any representation or warranty as to the accuracy or completeness of the Document or any statements, estimates or projections, and none will assume any liability for any representations (express or implied) contained in, or for any omissions from, the Document, or for any other written or oral communications transmitted to prospective investors in the course of their evaluation of the Company and its business. An investor will only be entitled to rely on those representations and warranties contained in the definitive agreement or agreements which constitute the financing. This presentation can not be copied, reproduced or distributed in whole or in part to others, at any time, without the prior express written consent of the Company. To the extent that they are included in this document, certain financial metrics can be reported as non-IFRS measures, such as EBITDA (earnings before interest, taxes, depreciation and amortization). For the purposes of this Document, EBITDA is calculated as revenue less cost of sales and operating expenses. The Company believes that these non-IFRS measures are appropriate measures of the operating performance of the Company. The Company’s calculation of these measures may differ from the methodology used by other issuers and, accordingly, may not be comparable to such other issuers. The Company believes that these measures are appropriate measures of the Company’s operating performance because they facilitate an understanding of operating performance without giving effect to certain non-cash and overhead expenses. None of these measures are equivalent to net income or cash flow from operating activities determined in accordance with IFRS. Aurora Cannabis Inc. Management Presentation 2
Highlights
1. Over 280,000 kg per year funded capacity
2. High-technology, ultra-efficient, low cost facilities
3. Strong revenue growth: last reported quarter (Q2 2018): 200% YoY and 41.8% QoQ
4. New production coming online, driving further growth
5. Continuously falling costs of production
6. Corporate expansion: 8 acquisitions and 7 strategic investments in past two years
7. Vertically integrated, horizontally diversified
8. Early mover advantage through rapidly growing international footprint
• Own EU’s largest distributor of cannabis
• Targeting international markets with nearly 800 million people and strong barriers to entry
• Already have presence/sales/agreements in Canada, Germany, Denmark, Italy, Australia, Cayman
Islands, South Africa
Driven by agility, innovation and execution
Aurora Cannabis Inc. Management Presentation 4
EXCEPTIONALLY PROJECTED MARKET POTENTIAL
WELL POSITIONED TO CANADA EU
$12 B1 $37 B1
CAPITALIZE ON THE
GLOBAL CANNABIS ROW
OPPORTUNITY $110 B1
AGILITY INNOVATION EXECUTION EXPANSION
1VIII Capital, Cannabis Sector, July 2017
Agility
Fastest Growing LP’s – Sales License to 650kg/quarter
• Fastest ramp up,
execution and sales
growth achieved
relative to other LP’s
• Focused strategy aimed
at capitalizing on
vertical and horizontal
integration Source: SEDAR filings
opportunities
internationally and 50,000
domestically 45,000
40,000
• High pace of execution 35,000
30,000
ensures early mover 25,000
advantage and rapid 20,000
capitalization on 15,000
opportunities 10,000
5,000
0
Jan-16
Apr-16
Oct-16
Nov-16
Dec-16
Jan-17
Apr-17
Oct-17
Nov-17
Dec-17
Jan-18
Feb-16
May-16
May-17
Sep-16
Feb-17
Sep-17
Feb-18
Mar-16
Jun-16
Aug-16
Jul-16
Mar-17
Jun-17
Aug-17
Jul-17
Mar-18
Aurora Cannabis Inc. Management Presentation 6
Innovation Across all Operational Areas
Establishing a world-leading brand, scale and efficiencies
CUSTOMER PRODUCTION INNOVAITON-
EXPERIENCE DRIVEN
PARTNERSHIPS
CUSTOMER EXPERIENCE AURORA LARSSEN PROJECTS RADIENT TECHNOLOGIES – disruptive
• The Aurora Standard: • World’s premier greenhouse design extraction technology for cannabis oil
leading edge customer care consultancy production
• Only LP with mobile app for AURORA SKY NAMASTEMD - exclusive white label
purchasing medical use for patient education and
• World’s largest capacity and most registration portal
cannabis technologically advanced cannabis
• Same-day delivery in cultivation facility MICRON WASTE TECHNOLOGIES (6.5%
Calgary, Edmonton and interest) – low-cost environmentally
• Optimized for highest yield and lowest friendly treatment of organic waste
surrounding areas cost per gram produced
• e-Commerce CANNAROYALTY – acquiring IP for
AURORA MOUNTAIN portfolio of novel drug delivery
• Product differentiation • World’s first fully purpose-built indoor technologies
cannabis facility, EU GMP certified
Aurora Cannabis Inc. Management Presentation 7
STRATEGY AND EXECUTION
200% Strong balance
DOMESTIC EXPANSION
YoY revenue sheet
growth
GLOBAL EXPANSION
VERTICAL INTEGRATION
Direct and 280,000 kg
indirect per annum
HORIZONTAL DIVERSIFICATION presence on funded
3 continents capacity
CAPITALIZATION
8 Acquisitions
7 Strategic investments
Multiple Strategic partnerships
8
Domestic Capacity Expansion
FACILITIES MOUNTAIN SKY VIE LACHUTE CANNIMED TGOD
Footprint 55,000 800,000 40,000 48,000 97,000 Relationship 17.62% ownership interest
(square
footage) Supply agreement for up
to 23,200 kgpa
Status Operational Licensed in January Completed Completion Working on GMP certification
since 2015 2018 and early calendar Status BuIlding Larssen-designed
Licensed 2018 Commenced expansion 102,000 kgpa facility in
Completion by mid- Nov 2017 Quebc
2018 Completing 14,000 kgpa
facility in Ontario
Capacity 4,800 kg/yr 100,000+ kg/yr 4,000+ kg/yr 4,500+ kg/yr 19,000 kg/yr Funded 116,000+ kg/yr
Capacity
Key First purpose Highly automated, Technologi Nearly Key features Premium organic
features built technologically cally completed, Current 7,000 kgéyr capacity cannabis producer
cannabis advanced cannabis advanced, state-of-the art to be expanded to 19,000 kg
facility facility for optimized specialty facility to be per year
yield and low cost strains for completed to
EU GMP production built to premium EU GMP
certified EU GMP standards. products standards
and
Located at
medical
Edmonton
research
international airport
for superior domestic
Completed
and global logistics
to EU GMP
standards
9
1 VIII Capital, Cannabis Sector, July 2017
CanniMed Acquisition
Cannabis Oils
Adding 19,000 kg per
annum funded • Significant sales acceleration since
launching oils in 2016
capacity • Phase 1 expansion - $1 billion revenue
Adding over 20,000 capacity with 70+% profit margins
Strong Brands patients
• 12 million bottles / year @ 165.00 per 60 ml
• Completed first oils export to Australia and
Expands international Cayman Islands
footprint • Extraordinary capability and expertise
Capsules Production
Well Connected To form core of Aurora’s
• Expected to accelerate growth in Canada
and internationally
Medical Cannabis • For baby boomers looking for a safe,
Centre of Excellence reliable way to manage their chronic pain
symptoms and maintain an active lifestyle
Topical Cream
Adds drug delivery
technologies • Recently launched leading trans-dermal
Major Expansion topical cream
Aurora Cannabis Inc. Management Presentation 10Denmark
International Expansion
Owns 51% of Aurora
Nordic where Europe’s
largest cannabis facility is
being built at 1,000,000
sq ft
• Potentially very large Germany European Union
markets Sells cannabis through Pedanios, LOI with Creso Pharma
leading wholesale Ltd. to market CMED
importer/exporter/distributer medical cannabis brands
• But with strong barriers
to entry
Italy
Sells cannabis to the
• Requires EU GMP Italian government
through Pedanios Australia
certification to
~588.8M
First ever shipment of
commercial cannabis oils
participate
• Aurora is one of few
Cayman Islands
First ever sale of =
combined
commercial cannabis
companies with such oils
certification population
Aurora
• Accelerating CanniMed
South Africa
Definitive agreement to Australia
international expansion Both Aurora & CanniMed supply cannabis products to
Akula Trading 2 Pty Ltd.
22.9% interest in Cann Group,
first Australian company
through CanniMed licenced to cultivate medical
cannabis
transaction
Aurora Cannabis Inc. Management Presentation 11$180B Medical Market Coming Online Over the Next 10-15 Years
Medical Market Sizes
Population Medical Implied Demand
Country Name of Regulation Year Voted In Flower + Extracts
(MM) Cannabis? (kg per year) If flower Only ($MM)
Eight Capital – 2018 Active Medical Cannabis Laws
($MM)
Outlook: legalization
Argentina 43.4 ✓ - 2017 316,820 $2,218 $3,564
Austria 8.5 ✓ - 2008 62,050 $434 $698
will lead to Australia
Canada
23.9
35.9
✓
✓
Narcotics Drug Amendment Bill
ACMPR
2016
2001
174,470
262,070
$1,221
$1834
$1,963
$2,948
Globalization Chile
Columbia
17.9
48.2
✓
✓
Decree 84
-
2015
2015
130,670
251,860
$915
$2,463
$1470
$3,958
Croatia 4.2 ✓ - 2015 30,660 $215 $345
Amendments 50/2013 Coll. &
Czech Republic 10.5 ✓ 221/2013 Coll.
2013 76,650 $537 $862
Germany 80.5 ✓ - 2017 589,110 $4,124 $6,627
• International medical Israel
Italy
8.1
59.8
✓
✓
-
-
1992
2007
59,130
436,540
$414
$3,056
$665
$4,911
market growing at a 21% Jamaica 2.8 ✓
Dangerous Drugs (Amendment) Act
2015
2015 20,440 $143 $230
Macedonia 2.1 ✓ - 2016 15,330 $107 $172
CAGR until 2025 Mexico
Netherlands
127
16.9
✓
✓
-
-
2017
2003
927,100
123,370
$6,490
$864
$10,430
$1,388
Norway 5.2 ✓ - 2016 37,960 $266 $427
• Near to mid-term Puerto Rico 3.7 ✓ - 2015 27,010 $189 $304
Romania 19.5 ✓ - 2013 142,350 $996 $1,601
expansion through Slovenia 2.1 ✓ -
Federal Act on Narcotics and
2014 15,330 $107 $172
Switzerland 8.3 ✓ 2008 60,590 $424 $682
medical-focused
Psychotropic Substances
Turkey 78.7 ✓ Legal in 19 provinces 2016 574,510 $4,022 $6,463
Uruguay 3.4 ✓ - 2013 24,820 $174 $279
opportunities Subtotal 610.8 4,358,840 $31,212 $50,162
Pending Medical Cannabis Laws or Countries of Interest
Belgium 11.3 - 82,490 $577 $928
• Multiple GMP-certified
-
Brazil 207.8 - - 1,516,940 $10,619 $17,066
Denmark 5.7 - - 41,610 $291 $468
facilities to export to Finland
France
5.5
64.4
-
-
-
-
40,150
470,120
$281
$3,291
$452
$5,289
international markets Iceland
Ireland
0.3
4.7
-
-
-
-
2,190
34,310
$15
$240
$25
$386
New Zealand 4.5 - - 32,850 $230 $370
Poland 38.6 - - 281,780 $1,972 $3,170
Portugal 10.4 - - 75,920 $531 $854
Slovakia 5.4 - - 39,420 $276 $443
South Africa 54.5 - - 397,850 $2,785 $4,476
Spain 46.1 - - 336,530 $2,356 $3,786
United Kingdom 64.7 - - 472,310 $3,306 $5,313
United States 321.8 Legal 29 states and D.C. - 2,349,140 $16,444 $26,428
Subtotal 845.7 6,173,610 $79,154 $127,212Pedanios – Aurora’s Gateway to the EU Cannabis Market
• Largest medical cannabis distributor in EU
(100% owned)
• EU GMP certified for import, release and
distribution of cannabis
• Currently servicing >2,000 pharmacies in
Germany (exclusive suppliers of patients)
• Access to single largest federally legalized
medical cannabis market with population
> 82 million
• Broad insurance coverage for prescribed
medical cannabis
• Limited number of EU GMP certified
international producers 82 million >400 million
• In phase 2 of tender process for German population Germany population EU
cultivation license
• Won first public tender to supply Italian system Cornerstone acquisition for European
expansion strategy 13Aurora Nordic – Europe’s Largest Facility
at 1,000,000 Square Feet
Nordic focus wth
• Aurora Nordic: 51/49 JV with Alfred option to export
Pedersen, one of Europe’s largest
greenhouse growers of vegetables to wider EU with
(>100,000 kg per day)
> 400 M people
• Licensed to produce as of Jan 1, 2018
• To construct ALPS-designed high-
technology facility
• At 1,000,000 sqft, this will be largest
cannabis facility in Europe JV Partner Recognized
• Focused on Nordic countries and as one of Denmark’s
export to rest of EU through Pedanios leading entrepreneurs
• Built to EU GMP standards for export
• Retrofitting existing greenhouse for 8,000
82 million
kgpa capacity while main facility is population Germany
being constructed
14Vertical Integration – Horizontal Diversification
Aurora – Industry Leading CanniMed – Strong International Presence
International Strategic Partnerships With Meaningful Distribution Partners
• Over the last two years, Aurora has completed 15 acquisitions and • CanniMed has built strong partnerships that position it well for future
strategic investments, including: growth:
o Pedanios – EU`s largest distributor of cannabis, based in o Avaria – CanniMed entered into an agreement with Avaria
Germany – EU GMP certified Health & Beauty Corp for the distribution of topical medical
o LIQ – Strategic investment in Western Canada’s largest liquor cannabis products, product development, and clinical
retail chain. LIQ to convert existing retail outlets and establish research
new ones for the sale of cannabis for the adult consumer use o PharmaChoice – Entered into Canada’s first exclusive
market pharmacy distribution agreement for medical cannabis
o Radient Technologies – Partnership for the high-throughput o Canadian Cancer Survivor Network – Partnered with Canadian
extraction of cannabinoids Cancer Survivor Network for medical cannabis education
Akula Trading 2 Pty Ltd.
15Adult Consumer Use Market – LIQ Partnership • Acquired 19.9% of issued and outstanding shares in Liquor Stores N.A. (“LIQ”), with option to increase ownership to 40% • LIQ will use proceeds to convert existing stores, as well as build new stores, into cannabis retail outlets • LIQ has strong presence in Western Canada with over 200 liquor stores • One of the dominant retail brands in Western Canada • Ensures LIQ and Aurora will be ready on Day One of the commencement of cannabis sales for the adult consumer market, once legalized • Leveraging LIQs deep expertise, capabilities and capacity in operating a network of retail outlets • Aurora to contribute branding, product knowledge and understanding of the cannabis culture and markets Aurora Cannabis Inc. Management Presentation 16
BC Northern Lights – Supporting the Home Grow Market
• The gold-standard in indoor grow boxes
• Only purpose-built growing appliance on the market
• Odor-free operation, ideal for multi-unit dwellings
• Lockable doors
• Only growing appliance that offers CSA/UL safety
approval
• Produced using premium materials and components
only
• Medical grade powder coated aluminum to avoid
any mold or mildew issues
• 20-year track record
• Exceptional customer care
• Customized nutrient management plans
• Unlimited toll-free technical support
• Live streaming “Growinars”
• BCNL customers can speak to experienced
growers and technicians seven days a week
Aurora Cannabis Inc. Management Presentation 17FINANCIAL SECTION
18Strong Revenue Growth
Sequential
Growth (%) 457.1% 151.7% 26.5% 33.2% 14.7% 39.0% 41.8%
200%
Revenue ($M) $14.00
$12.00
YoY growth
for Q2 2018
$10.00
$8.00
$6.00
$4.00
$2.00
$0.00
Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018
Aurora Cannabis Inc. Management Presentation 19Rapid Development Relative to Sector
LPs Revenue Development
25
20
15
10
5
0
Dec-14 Mar-15 Jun-15 Sep-15 Dec-15 Mar-16 Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Sep-17 Dec-17
ACB WEED APH LEAF CMED ACB+CMED
Notes to chart: LPs have different reporting schedules. For comparison reasons, revenues
have been assigned to the corresponding Aurora quarter.
Aurora Cannabis Inc. Management Presentation 20Strong Execution Drives Fastest Revenue Development
Revenue development first 8 quarters Revenue development since ACB
from commencement of sales commenced sales
14 25
12
20
10
15
8
6
10
4
5
2
0 0
1Q 2Q 3Q 4Q 5Q 6Q 7Q 8Q
Apr-16
Sep-16
Oct-16
Nov-16
Dec-16
Jan-17
Apr-17
Sep-17
Oct-17
Nov-17
Dec-17
May-16
Jun-16
Feb-17
May-17
Jun-17
Mar-16
Aug-16
Aug-17
Jul-16
Mar-17
Jul-17
ACB WEED APH
ACB WEED APH LEAF CMED ACB+CMED
Aurora Cannabis Inc. Management Presentation 21Continuously Improving Metrics
Q2 2018 Q1 2018 Q4 2017 Q3 2017 Q2 2017
# # # # #
(1)
Active registered patients 23,000 19,280 16,400 13,110 12,200
Grams sold 1,161,809 889,965 755,059 653,008 538,045
(2)
Grams produced 1,204,259 1,009,585 1,164,683 846,849 670,322
(In CDN $000’s unless otherwise noted) $ $ $ $ $
Average net selling price per gram 8.36 8.22 7.45 6.64 5.96
Cash cost of sales per gram 1.74 1.92 2.09 2.31 2.56
Cash cost to produce per gram 1.41 1.73 1.91 1.91 2.13
Cash and cash equivalents 350,841 127,915 159,796 111,116 55,846
Aurora Cannabis Inc. Management Presentation 22Value Creation Through Strategic Investments
Shares Average Current
Company invested in RoI
bought price Value
#(million) $ (million) $ (million) %
Cann Group 28.8 0.84 82.9
Radient Technologies 23.2 0.57 38.5
Hempco Food and Fiber 10.6 0.31 11.4
Micron Waste Technologies 4.4 0.34 2.1
TOTAL 135 >200%
Exceptional investment track record
Also completed $55 million investment into The Green Organic Dutchman (private)
Aurora Cannabis Inc. Management Presentation 23HIGHLIGHTS
SCALE
• Upon completion, six facilities
• > 280,000 kg per annum funded production capacity
• Technologically most advanced facilities => ultra low
cost of production
• CanniMed acquisition
Fastest patient sign up
INTERNATIONAL EXPANSION rate in industry
• Pedanios - Germany & EU Scale to service both
• Cann Group – Australia
rapidly growing medical
• Aurora Nordic - Denmark
market and seize
INNOVATION legalization opportunity
• Disruptive extraction technology
• First mobile app for ordering medical cannabis Extremely well capitalized
• Customer care: same day delivery in two to pursue global
metropolitan areas expansion opportunity
DIFFERENTIATION/DIVERSIFICAITON
• Technology-driven cultivation philosophy to produce
high-quality cannabis at ultra low cost
• Diversifying product offering into adjacent markets, 24
accessing additional revenue streamsCompany Information
25Experienced Leadership Team
Terry Booth Cam Battley Darryl Vleeming
CEO Chief Corporate Officer Chief Information Officer
CEO of 6 successful companies Deep experience in pharma and over 20 years of experience in
25 years experience in highly cannabis sectors Senior IT leadership, project
regulated industries Board member Cannabis delivery, and IT strategic planning
Canada at publicly traded international
corporations, with a specific
focus on driving business value.
Steve Dobler Glen Ibbott
President CFO
Successful entrepreneur, member of Strong senior financial executive
many public companies’ board of with deep life sciences sector
directors. Responsible for raising experience
substantial funds for Aurora
Neil Belot Allan Cleiren
Chief Global Business COO
Development Officer Experienced operational
Former executive director of executive with nearly three
Cannabis Canada - Canada's trade decades leadership experience
association for Licensed Producers at private and public companies
Aurora Cannabis Inc. Management Presentation 26Board of Directors
Michael Singer Adam Szweras
Chairman Partner, Fogler, Rubinoff LLP
Experienced securities
CFO, Clementia
lawyer. Founder of a US
Pharmaceuticals
developer of marijuana
Former CFO, Bedrocan
and hemp oil, and edible
Cannabis Corp.
products.
Steve Dobler Dr. Jason Dyck
President, Aurora Professor, Department of
Successful entrepreneur, Pediatrics and Director of
member of many public Cardiovascular
companies’ board of Research Centre,
directors. Responsible for University of Alberta
raising substantial funds
for Aurora
Diane Jang Terry Booth
A business consultant, CEO, Aurora
specializing in strategic CEO of 6 successful
planning for sustainable companies
success, growth and 25 years experience
profitability, with over 27 in highly regulated
years of business industries
experience in the
Consumer Packaged
Goods industry
Aurora Cannabis Inc. Management Presentation 27AGILITY INNOVATION EXECUTION EXPANSION
Talented, experienced management team driving the sector's
fastest growth in customers, revenues and shareholder value
28Aurora Information
Established ~750 Employees Head Office
2013 6 Directors 1500 -1199 West Hastings St.
Vancouver, BC V6E 3T5
TSX: OTCQX:
ACB ACBFF
Aurora Cannabis Inc. Management Presentation 29Capital Summary
April 3, 2018
TSX listed, ticker symbol ACB
Securities Market Cap - Basic
Issued & Outstanding Shares* 561,061,244 $4.5 Billion
Options 25,087,884
Warrants 8,615,348
Share Price - April 3,
Convertible debentures shares
17,976,203 2018
reserved for issuance
$8.07
Fully Diluted 614,890,679
Strong balance sheet to fuel further growth
Aurora Cannabis Inc. Management Presentation 30Contact Information
Cam Battley Marc Lakmaaker, Director IR &
Chief Corporate Officer Corporate Development
+1 (905) 878-5525 +1 (647) 269-5523
cam@auroramj.com Marc.lakmaaker@auroramj.com
31You can also read
